Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Indian Pharma Expands Generic Semaglutide Globally; Sanofi India Focuses on Insulin Growth

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Indian Pharma Expands Generic Semaglutide Globally; Sanofi India Focuses on Insulin Growth

Analysed 18 Nov 2026·2 sources analysed·India·Business
Indian Pharma Expands Generic Semaglutide Globally; Sanofi India Focuses on Insulin GrowthPreviousNext

Indian pharmaceutical companies are expanding their generic semaglutide offerings internationally following patent expiry, with Dr Reddy's, Sun Pharma, and Hetero leading launches and partnerships. Dr Reddy's targets significant supply volumes despite recent recalls affecting Canadian shipments. Meanwhile, Sanofi India is focusing on growth through its insulin franchise and specialty-care launches after restructuring, reporting increased revenues and profits. The company has streamlined its portfolio and partnered with firms like Emcure and Cipla to promote mature brands, emphasizing execution and sustainable growth amid rising competition.

Sentiment
61%
TBN's observations

First-hand measurement across 2 sources

We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (61/100). Lens Score 52/100.

Outlets measured: businessstandard, moneycontrol. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 18 Nov 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Positive (61/100)

Sentiment was consistent across outlets (52–70/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

moneycontrol broke this story on 18 Nov, 07:46 am. Other outlets followed.

18 Nov, 07:46 am2 sources · 2 h18 Nov, 09:59 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Xiaomi Faces Over Rs. 1,350 Crore Tax Dispute Over Undisclosed Royalty Payments in India
Next →
Nasdaq Plans Extended US Trading Hours; SEBI Cites Risks in 24x7 Trading for India
1
moneycontrol18 Nov, 07:46 am
Sanofi bets on insulin franchise, innovation launches to drive growth after restructuring- Moneycontrol.com
  • 2
    businessstandard18 Nov, 09:59 am
    Indian drugmakers take generic semaglutide battle to overseas markets
  • Who's involved

    Institutions and figures named across source coverage.

    Government
    Brazilian Health Regulatory AgencyUnited States Food and Drug AdministrationSouth African Medicines Regulator
    Corporate
    Dr Reddy's LaboratoriesCipla LimitedBiocon LimitedAjanta Pharma LimitedGufic Biosciences LimitedSun Pharmaceutical Industries LimitedHetero Drugs LimitedDr Reddy's Laboratories LimitedLupin LimitedSandozSanofi India Private LimitedEmcure Pharmaceuticals LimitedNovo Nordisk

    Story context

    Category
    Business
    Location
    India
    Sources analysed
    2
    Last analysed
    18 Nov 2026
    Key entities
    Glucagon-like peptide-1IndiaDiabetesChief executive officerCroreIndian rupeeSun PharmaSemaglutideDr. Reddy's LaboratoriesNovo NordiskPatentFood and Drug Administration